[go: up one dir, main page]

PL3207149T3 - Kompozycja farmaceutyczna o zwiększonej stabilności - Google Patents

Kompozycja farmaceutyczna o zwiększonej stabilności

Info

Publication number
PL3207149T3
PL3207149T3 PL15850568.5T PL15850568T PL3207149T3 PL 3207149 T3 PL3207149 T3 PL 3207149T3 PL 15850568 T PL15850568 T PL 15850568T PL 3207149 T3 PL3207149 T3 PL 3207149T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
increased stability
stability
increased
pharmaceutical
Prior art date
Application number
PL15850568.5T
Other languages
English (en)
Inventor
Yuhua Li
Andrew J. Guarino
Original Assignee
Foresee Pharmaceuticals Co., Ltd.
Yuhua Li
Andrew J. Guarino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foresee Pharmaceuticals Co., Ltd., Yuhua Li, Andrew J. Guarino filed Critical Foresee Pharmaceuticals Co., Ltd.
Publication of PL3207149T3 publication Critical patent/PL3207149T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00Preparation of nitrogen-containing organic compounds
    • C12P13/04Alpha- or beta- amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15850568.5T 2014-10-15 2015-10-15 Kompozycja farmaceutyczna o zwiększonej stabilności PL3207149T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064008P 2014-10-15 2014-10-15
PCT/US2015/055634 WO2016061296A1 (en) 2014-10-15 2015-10-15 Pharmaceutical composition with improved stability

Publications (1)

Publication Number Publication Date
PL3207149T3 true PL3207149T3 (pl) 2023-08-21

Family

ID=55747307

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15850568.5T PL3207149T3 (pl) 2014-10-15 2015-10-15 Kompozycja farmaceutyczna o zwiększonej stabilności

Country Status (20)

Country Link
US (3) US20160106804A1 (pl)
EP (1) EP3207149B1 (pl)
JP (2) JP6717839B2 (pl)
KR (2) KR102274420B1 (pl)
CN (2) CN113209009B (pl)
AU (2) AU2015332456A1 (pl)
BR (1) BR112017007669A2 (pl)
CA (1) CA2964475C (pl)
ES (1) ES2949827T3 (pl)
HR (1) HRP20230716T1 (pl)
HU (1) HUE062326T2 (pl)
IL (1) IL251703B (pl)
MX (2) MX392770B (pl)
PL (1) PL3207149T3 (pl)
RS (1) RS64339B1 (pl)
RU (1) RU2728786C2 (pl)
SA (1) SA517381298B1 (pl)
SG (1) SG11201702535QA (pl)
SM (1) SMT202300196T1 (pl)
WO (1) WO2016061296A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
JP7125403B2 (ja) * 2017-01-04 2022-08-24 ファーマシェン エス.エー. 高分子量の生分解性ポリマーを調製するための方法
WO2018144603A1 (en) * 2017-01-31 2018-08-09 Veru Inc. COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GANADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
US20200282008A1 (en) * 2017-01-31 2020-09-10 Veru Inc. COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
GB2568526A (en) 2017-11-20 2019-05-22 Rebio Tech Oy Composition
SG11202004525TA (en) * 2017-12-18 2020-06-29 Foresee Pharmaceuticals Co Ltd Pharmaceutical compositions having a selected release duration
JP2024530015A (ja) 2021-08-05 2024-08-14 メドインセルル エス.エー. 医薬組成物
CN116982619A (zh) * 2023-08-04 2023-11-03 洛阳奇泓生物科技有限公司 丙交酯-Nisin固体分散体及其制备

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3708916A1 (de) 1987-03-19 1988-09-29 Boehringer Ingelheim Kg Verfahren zur reinigung resorbierbarer polyester
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
ATE168391T1 (de) 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
FI933471L (fi) 1991-12-19 1993-08-05 Mitsui Toatsu Chemicals Polyhydroxikarboxylsyra och foerfarande foer dess framstaellning
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5681873A (en) 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
DK1125577T3 (da) 1994-04-08 2006-06-19 Qlt Usa Inc Væskeformige medikamentindföringspræparater
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
FR2776516B1 (fr) * 1998-03-25 2001-05-25 Pharma Biotech Compositions presentant une liberation prolongee et leur procede de preparation
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
CA2355186C (en) 1998-12-15 2008-03-18 Takeda Chemical Industries, Ltd. Process for producing polymer
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
KR100321854B1 (ko) * 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2819769C (en) * 2003-07-18 2016-06-28 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
DK1824460T3 (en) 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
CN101400363B (zh) 2006-01-18 2012-08-29 昌达生物科技公司 具有增强的稳定性的药物组合物
CN101511380B (zh) * 2006-07-11 2012-12-12 昌达生物科技公司 用于持续释放递送肽的药物组合物
PL3660073T3 (pl) * 2007-02-15 2023-12-27 Tolmar International Limited Poli(laktyd-ko-glikolid) o niskim nagłym uwalnianiu
US9090737B2 (en) * 2007-11-13 2015-07-28 Surmodics, Inc. Viscous terpolymers as drug delivery platform
CN102958512B (zh) 2008-08-29 2015-04-29 健赞股份有限公司 控释肽制剂
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability

Also Published As

Publication number Publication date
KR102134873B1 (ko) 2020-07-17
CA2964475C (en) 2020-03-24
EP3207149A1 (en) 2017-08-23
US20250041378A1 (en) 2025-02-06
SA517381298B1 (ar) 2021-12-18
SMT202300196T1 (it) 2023-09-06
US20220160817A1 (en) 2022-05-26
CA2964475A1 (en) 2016-04-21
WO2016061296A1 (en) 2016-04-21
JP6928695B2 (ja) 2021-09-01
KR20170070176A (ko) 2017-06-21
AU2019279929B2 (en) 2021-02-25
AU2015332456A1 (en) 2017-04-13
CN107075541A (zh) 2017-08-18
RU2017111079A3 (pl) 2019-05-17
KR20190029783A (ko) 2019-03-20
IL251703B (en) 2021-03-25
SG11201702535QA (en) 2017-04-27
EP3207149C0 (en) 2023-06-07
BR112017007669A2 (pt) 2017-12-19
HUE062326T2 (hu) 2023-10-28
US20160106804A1 (en) 2016-04-21
JP2017531697A (ja) 2017-10-26
RU2017111079A (ru) 2018-11-15
CN113209009A (zh) 2021-08-06
JP6717839B2 (ja) 2020-07-08
EP3207149A4 (en) 2018-06-13
MX392770B (es) 2025-03-19
MX2017005235A (es) 2019-12-11
MX2022003939A (es) 2022-04-25
RS64339B1 (sr) 2023-08-31
RU2728786C2 (ru) 2020-07-31
IL251703A0 (en) 2017-06-29
KR102274420B1 (ko) 2021-07-08
JP2020147595A (ja) 2020-09-17
CN113209009B (zh) 2024-08-20
CN107075541B (zh) 2021-06-25
EP3207149B1 (en) 2023-06-07
NZ730538A (en) 2024-01-26
AU2019279929A1 (en) 2020-01-16
ES2949827T3 (es) 2023-10-03
HRP20230716T1 (hr) 2023-10-13

Similar Documents

Publication Publication Date Title
EP3513809A4 (en) MEDICAL COMPOSITION
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
DK3140008T3 (da) Hurtigtvirkende insulinsammensætninger
BR112016023628A2 (pt) composições farmacêuticas.
DK3040326T3 (da) Haloolefin-baseret sammensætning
BR112016026879A2 (pt) Composição farmacêutica líquida
FR3024363B1 (fr) Composition thermogelifiable
DK3199161T3 (da) Farmaceutisk præparat
CL2015001019S1 (es) Ampolleta
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
DK3363428T3 (da) Perfusionsdoseringsform
PL3207149T3 (pl) Kompozycja farmaceutyczna o zwiększonej stabilności
CL2017000639A1 (es) Composición
DK3275452T3 (da) Farmaceutisk sammensætning med silibinin
DK3322295T3 (da) Sammensætning
EP3236746C0 (en) COMPOSITION
DK3140050T3 (da) Dosering med visning
DK3148513T3 (da) Ceritinib-formulering
EP3395344A4 (en) MEDICINE
DK3288967T3 (da) Farmaceutisk forbindelse
DK3217964T3 (da) Sammensætning
DK3089740T3 (da) Farmaceutisk sammensætning
DK3193856T3 (da) Formulering
FR3019552B1 (fr) Composition filmogene
EP3441073A4 (en) MEDICAL COMPOSITION